Patents by Inventor Gnanasambandam Kumaravel

Gnanasambandam Kumaravel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10034869
    Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: July 31, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel
  • Patent number: 10030016
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: July 24, 2018
    Assignees: Sunesis Pharmaceuticals, Inc., Millenium Pharmaceuticals, Inc.
    Inventors: Joseph Arndt, Timothy Chan, Kevin Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Daniel Scott, Lihong Sun, Jermaine Thomas, Kurt van Vloten, Deping Wang, Lei Zhang, Daniel Erlanson
  • Patent number: 10017506
    Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: July 10, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Deping Wang, Zhili Xin, Lei Zhang
  • Publication number: 20180133233
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 17, 2018
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 9963448
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 8, 2018
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Michael F. Parker, Edward Beaumont, Lee Bowles, Steve Bromidge, Sophie Cooper, Elise Gadouleau, Laura Gleave, Philip Kerry, Adrian Kotey, Thomas Krulle, Cristina Lecci, Pui Loke, Mirco Meniconi, Nat Monck, Carl North, Jordan Palfrey, Shelley Parrott, Mark Ridgill, Heather Tye
  • Patent number: 9944666
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 17, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Kevin M. Guckian, Gnanasambandam Kumaravel, Bin Ma, Sha Mi, Hairuo Peng, Zhaohui Shao, Lihong Sun, Arthur G. Taveras, Zhili Xin, Lei Zhang
  • Publication number: 20180093973
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: December 20, 2017
    Publication date: April 5, 2018
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • Patent number: 9920048
    Abstract: The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I: or a pharmaceutically acceptable salt thereof, wherein Rx, Ry, R1, L1, L2, Cy1, and Cy2 are as defined as set forth in the specification.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 20, 2018
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Jennifer Cossrow, Lloyd Franklin, Bing Guan, John Howard Jones, Gnanasambandam Kumaravel, Benjamin Lane, Adam Littke, Alexey Lugovskoy, Hairuo Peng, Noel Powell, Brian C. Raimundo, Hiroko Tanaka, Jeffrey Vessels, Thomas Wynn, Zhili Xin
  • Publication number: 20180065974
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 8, 2018
    Inventors: Minna BUI, Patrick CONLON, Julio H. CUERVO, Daniel A. ERLANSON, Junfa FAN, Bing GUAN, Brian T. HOPKINS, Tracy J. JENKINS, Gnanasambandam KUMARAVEL, Alexey A. LUGOVSKOY, Doug MARCOTTE, Noel POWELL, Daniel SCOTT, Laura SILVIAN, Art TAVERAS, Deping WANG, Min ZHONG
  • Publication number: 20180028511
    Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
    Type: Application
    Filed: July 7, 2017
    Publication date: February 1, 2018
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel
  • Publication number: 20180002356
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: June 13, 2017
    Publication date: January 4, 2018
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • Patent number: 9850206
    Abstract: Compounds of formula (I) wherein: X is —O—, —S(O)r—, —CH2—, or —NR—, wherein r is 0, 1, or 2; X1, X2, and X5 are each independently CR7 or N; one of X3 or X4 is C and is attached by a single bond to -L-, and the other is CR7 or N, provided that no more than three of X1, X2, X3, X or X5 are N; Ring A is monocyclic C5-6scycloalkyl or a 5- to 6-membered monocyclic heterocyclyl comprising from 1 to 5 heteroatoms independently selected from N, S, or O; wherein Ring A is further optionally substituted with from 1 to 3 R4; provided that Ring A is not morpholinyl, thiomorpholinyl or tetrahydro-2H-pyranyl; L is a bond, —O—, —NR—, —S(O)n—, —CH2—, or —C(O)—, wherein n is 0, 1, or 2; 1 2 L1 is an C1-8alkylene, C3-scycloalkylene, —CH2-L2-, or a 3- to 8-membered heterocyclylene comprising 1 to 5; R1 is C6-20alkyl or a monocyclic C3-8cycloalkyl; wherein said C3-8cycloalkyl is substituted with at least one R6 and may be optionally substituted with from 1 to 5 additional R6 substituents, wherein R6 for each occurrence is inde
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: December 26, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Hairuo Peng, Edward Yin-Shiang Lin, Jianhua Chao, Zhili Xin, Bin Ma, Kevin Guckian, Timothy Chan, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 9827258
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Grant
    Filed: January 3, 2017
    Date of Patent: November 28, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 9809577
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: November 7, 2017
    Assignee: Biogen MA Inc.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • Patent number: 9808449
    Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: November 7, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
  • Patent number: 9790229
    Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 17, 2017
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: Minna Bui, Patrick Conlon, Julio H. Cuervo, Daniel A. Erlanson, Junfa Fan, Bing Guan, Brian T. Hopkins, Tracy J. Jenkins, Gnanasambandam Kumaravel, Alexey A. Lugovskoy, Doug Marcotte, Noel Powell, Daniel Scott, Laura Silvian, Art Taveras, Deping Wang, Min Zhong
  • Patent number: 9771326
    Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: September 26, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Hairuo Peng, Zhili Xin, Lihong Sun, Timothy Chan, Gnanasambandam Kumaravel, Arthur G. Taveras
  • Patent number: 9765093
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 19, 2017
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Laura Gleave, Adrian Kotey, Thomas Krulle, Cristina Lecci, Heather Tye, Ian Wigginton
  • Patent number: 9765016
    Abstract: Compounds of formula (I) can modulate the activity of one or more S 1P receptors. Sphingosine 1-phosphate (S IP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family, namely S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDG8). The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (Ga.) subunits and beta-gamma (G( )y) dimers.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: September 19, 2017
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Xiaogao Liu, Bin Ma, Hairuo Peng
  • Publication number: 20170239280
    Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
    Type: Application
    Filed: January 3, 2017
    Publication date: August 24, 2017
    Inventors: Jermaine Thomas, Xiaogao Liu, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Arthur G. Taveras